title: Phage neutralization by sera of patients receiving phage therapy.
abstract: The aim of our investigation was to verify whether phage therapy (PT) can induce antiphage antibodies. The antiphage activity was determined in sera from 122 patients from the Phage Therapy Unit in Wrocław with bacterial infections before and during PT, and in sera from 30 healthy volunteers using a neutralization test. Furthermore, levels of antiphage antibodies were investigated in sera of 19 patients receiving staphylococcal phages and sera of 20 healthy volunteers using enzyme-linked immunosorbent assay. The phages were administered orally, locally, orally/locally, intrarectally, or orally/intrarectally. The rate of phage inactivation (K) estimated the level of phages' neutralization by human sera. Low K rates were found in sera of healthy volunteers (K ≤ 1.73). Low K rates were detected before PT (K ≤ 1.64). High antiphage activity of sera K > 18 was observed in 12.3% of examined patients (n = 15) treated with phages locally (n = 13) or locally/orally (n = 2) from 15 to 60 days of PT. High K rates were found in patients treated with some Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecalis phages. Low K rates were observed during PT in sera of patients using phages orally (K ≤ 1.04). Increased inactivation of phages by sera of patients receiving PT decreased after therapy. These results suggest that the antiphage activity in patients' sera depends on the route of phage administration and phage type. The induction of antiphage activity of sera during or after PT does not exclude a favorable result of PT.
authors.forename: Marzanna
authors.initials: M
authors.lastname: Łusiak-Szelachowska
authors.forename: Maciej
authors.initials: M
authors.lastname: Zaczek
authors.forename: Beata
authors.initials: B
authors.lastname: Weber-Dąbrowska
authors.forename: Ryszard
authors.initials: R
authors.lastname: Międzybrodzki
authors.forename: Marlena
authors.initials: M
authors.lastname: Kłak
authors.forename: Wojciech
authors.initials: W
authors.lastname: Fortuna
authors.forename: Sławomir
authors.initials: S
authors.lastname: Letkiewicz
authors.forename: Paweł
authors.initials: P
authors.lastname: Rogóż
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Szufnarowski
authors.forename: Ewa
authors.initials: E
authors.lastname: Jończyk-Matysiak
authors.forename: Barbara
authors.initials: B
authors.lastname: Owczarek
authors.forename: Andrzej
authors.initials: A
authors.lastname: Górski
mesh_terms: D000914:Antibodies, Viral / Q000097:blood*; D001424:Bacterial Infections / Q000628:therapy*; D001435:Bacteriophages / Q000276:immunology*; D016022:Case-Control Studies; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D009500:Neutralization Tests; D038301:Virus Inactivation
chemical_list: D000914:Antibodies, Viral